

In the matter of the Canadian Anti-Doping Program;

**And in the matter of an anti-doping rule violation by Darien Newell asserted by the Canadian
Centre for Ethics in Sport;**

File Outcome Summary

Summary

1. Darien Newell (the “Athlete”) was selected for Doping Control at an Out-of-Competition Sample collection session on March 19, 2025, in Regina, SK, at the Canadian Football League (CFL) Combine, under the CFL’s authority.
2. Subsequently, the CCES was made aware of an anti-doping rule violation, following the Public Disclosure of the Athlete’s violation of the CFL/CFLPA Policy to Prevent the Use of Performance Enhancing Drugs for the presence of multiple Prohibited Substances.
3. Following a review, the CCES was satisfied that, at the time of Sample collection, the Athlete was subject to the Canadian Anti-Doping Program (CADP) given the Athlete had one (1) year of eligibility remaining with U SPORTS.
4. The Sample provided by the Athlete returned Adverse Analytical Findings (AAFs) for GW501516 metabolites (sulfone and sulfoxide) (GW501516), SARM Ostarine (S-22), SARM LGD-4033 and bishydroxylated metabolite (SARM LGD-4033), Ibutamoren and metabolite (desbenzyl ibutamoren) (Ibutamoren), Nandrolone and metabolites (Nandrolone), Testosterone, Drostanolone metabolite (Drostanolone), Norclostebol metabolite (Norclostebol), and Oxandrolone metabolites (Oxandrolone), all non-Specified Substances included on the World Anti-Doping Agency’s (WADA) 2025 Prohibited List.
5. The Athlete failed to dispute the asserted anti-doping rule violation (ADRV), as outlined in the CCES’s Notice of Charge letter, and was therefore deemed to have admitted the ADRV, waived his right to a hearing and to have accepted all applicable Consequences.

Jurisdiction

6. The CCES is an independent not-for-profit organization incorporated under the federal laws of Canada that promotes ethical conduct in all aspects of sport in Canada and is responsible for handling the administration of the CADP, including providing anti-doping services to national Sport Organizations and their members.
7. As Canada’s National Anti-Doping Organization, the CCES is compliant the World Anti-Doping Code (“the Code”) and its mandatory International Standards. The CCES has implemented the Code and the International Standards through the CADP, the domestic rules which govern this proceeding. The purpose of the Code and of the CADP is to protect the rights of athletes to fair competition.
8. Following a review of the Athlete’s U SPORTS eligibility at the time of Sample collection, it was determined that the Athlete remained a member of U SPORTS. According to CADP Rule

1.3, the CADP provisions apply to all members of and Participants in activities of adopting Sport Organizations. The CADP was issued for adoption by Canadian Sport Organizations on October 26, 2020. U SPORTS adopted the CADP on January 27, 2021. Therefore, the Athlete was subject to the CADP.

Results Management

9. Following the CFL's Public Disclosure of the ADRV and given the Athlete's remaining U SPORTS eligibility, the CCES commenced an initial review of the matter under the CADP and requested the Certificate of Analysis from the CFL which was received on June 2, 2025.
10. According to the Certificate of Analysis, issued by the INRS Centre Armand-Frappier Santé Biotechnologie ("the INRS"), a WADA-accredited laboratory in Laval, QC, the Athlete's Sample was received for analysis on March 21, 2025.
11. On April 4, 2025, the INRS reported AAFs for the Athlete's Sample. The Certificate of Analysis indicated the presence of GW501516, SARM Ostarine (S-22), SARM LGD-4033, Ibutamoren, Nandrolone, Testosterone, Drostanolone, Norclostebol, and Oxandrolone.
12. GW501516, SARM Ostarine (S-22), SARM LGD-4033, Ibutamoren, Nandrolone, Testosterone, Drostanolone, Norclostebol, and Oxandrolone are classified as non-Specified Substances on WADA's 2025 Prohibited List and are prohibited at all times.
13. On June 23, 2025, the CCES issued a Notification of a potential ADRV to the Athlete, through U SPORTS, for the presence and Use of Prohibited Substances and imposed a Provisional Suspension on the Athlete pursuant to CADP Rule 7.4.1.
14. On July 24, 2025¹, the CCES formally issued a Notice of Charge asserting an ADRV against the Athlete for the presence and Use of the Prohibited Substances.
15. The CCES asserted a four (4) year period of Ineligibility to the Athlete in accordance with CADP Rule 10.2.1.1 along with an additional two (2) year period of Ineligibility for Aggravating Circumstances due to the presence of multiple Prohibited Substances, for a **total period of Ineligibility of six (6) years**, pursuant to CADP Rule 10.4.

Confirmation of Violation and Sanction

16. In accordance with CADP Rule 8.4.2, the CCES informed the Athlete in the Notice of Charge that a failure to dispute the asserted violation by August 13, 2025, would result in them being deemed to have admitted the violation, waiving their right to a hearing, and accepting the applicable Consequences.
17. The Athlete failed to dispute the asserted violation by the applicable deadline; therefore, the Athlete was deemed to have admitted the violation, waived their right to a hearing, and to have accepted all applicable Consequences pursuant to CADP Rule 8.4.2.

¹ The CCES notes that while the Notice of Charge was sent by email on July 24, 2025, the letter itself is dated July 23, 2025.

18. Effective August 13, 2025, an ADRV was confirmed against the Athlete for the presence and Use of the identified Prohibited Substances. The sanction for this violation is a six (6) year period of Ineligibility which commenced on June 23, 2025 (the date the Athlete was provisionally suspended) and concludes on June 22, 2031.
19. Further, in accordance with CADP Rules 9 and 10.10, any competitive results obtained by the Athlete from the date of Sample collection until the date the Athlete was provisionally suspended shall be Disqualified.
20. The CCES now considers this case closed.

Dated at Ottawa, Ontario this 11th day of September 2025.



Kevin Bean
Executive Director, Sport Integrity
CCES